merged_alzheimers-treatment-kisunla-donanemab.txt


<question_number>1</question_number>
<answer>significant safety risks including swelling and bleeding in the brain</answer>
<question_number>2</question_number>
<answer>it might discourage patients from participating in trials for better treatments</answer>
<question_number>3</question_number>
<answer>no correlation between amyloid removal and clinical response in individual subjects</answer>
<question_number>4</question_number>
<answer>N/A</answer>
<question_number>5</question_number>
<answer>patients can stop the drug after clearing amyloid, reducing long-term cost and side effects</answer>
<question_number>6</question_number>
<answer>it might reduce willingness to participate in other clinical trials</answer>
<question_number>7</question_number>
<answer>patients can discontinue treatment once amyloid is cleared</answer>
<question_number>8</question_number>
<answer>amyloid</answer>
<question_number>9</question_number>
<answer>Dr. Michael Greicius</answer>
<question_number>10</question_number>
<answer>intermediate tau levels</answer>